CXCL1

A board to discuss future MS therapies in early stage (Phase I or II) trials.

CXCL1

Postby scoobyjude » Sat Jan 03, 2009 10:56 pm

CXCL1 Decreases Severity Of Multiple Sclerosis-like Disease
Main Category: Multiple Sclerosis
Also Included In: Neurology / Neuroscience
Article Date: 03 Jan 2009 - 0:00 PST

A group led by Dr. Cedric Raine at Albert Einstein College of Medicine have explored the expression of an immune molecule (CXCL1) that interacts with myelin-producing cells, finding that CXCL1 decreases the severity of disease in a mouse model of multiple sclerosis (MS). They report their data in the January 2009 issue of The American Journal of Pathology.

The autoimmune disease multiple sclerosis (MS) attacks the central nervous system, resulting in demyelination of neurons. Myelin-producing cells in the central nervous system are severely depleted in lesions in patients with MS.

Myelin-producing cells express immune receptors and have been shown to respond to the immune molecule CXCL1, although the role of CXCL1 in MS has not been previously explored. Dr. Raine and colleagues examined the effects of CXCL1 specifically expressed in the nervous system in a mouse model of MS. They observed decreased severity of disease and more prominent remyelination in these mice. CXCL1, therefore, may play a neuroprotective role in CNS autoimmune demyelination.

In future studies, Dr. Raine's group plans to determine how CXCL1 mediates protection in MS. "Exploration of these pathways affords novel therapeutic avenues to enhance the limited remyelination typically seen in MS."

Omari KM, Lutz SE, Santambrogio L, Lira SA, Raine CS
"Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1."
Am J Pathol 2009, 174:164-176
User avatar
scoobyjude
Family Elder
 
Posts: 516
Joined: Sat Feb 18, 2006 4:00 pm
Location: suburb of Chicago, IL USA

Advertisement

Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service